Related CAS #
Src I1; Src I-1; SrcI1.
Synonym
Src I1; Src I-1; SrcI1.
IUPAC/Chemical Name
6,7-Dimethoxy-N-(4-phenoxyphenyl)-4-quinazolinamine
InChi Key
DMWVGXGXHPOEPT-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H19N3O3/c1-26-20-12-18-19(13-21(20)27-2)23-14-24-22(18)25-15-8-10-17(11-9-15)28-16-6-4-3-5-7-16/h3-14H,1-2H3,(H,23,24,25)
SMILES Code
COC1=CC2=NC=NC(NC3=CC=C(OC4=CC=CC=C4)C=C3)=C2C=C1OC
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
Src I1 is an Src kinase inhibitor (IC50s = 44 and 88 nM for Src and Lck, respectively).
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMSO |
9.1 |
24.34 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
373.41
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Keresztes A, Olson K, Nguyen P, Lopez-Pier MA, Hecksel R, Barker NK, Liu Z, Hruby V, Konhilas J, Langlais PR, Streicher JM. Antagonism of the mu-delta opioid receptor heterodimer enhances opioid antinociception by activating Src and calcium/calmodulin-dependent protein kinase II signaling. Pain. 2022 Jan 1;163(1):146-158. doi: 10.1097/j.pain.0000000000002320. PMID: 34252907; PMCID: PMC8688156.
2: Bozhokina ES, Tsaplina OA, Khaitlina SY. The Opposite Effects of ROCK and Src Kinase Inhibitors on Susceptibility of Eukaryotic Cells to Invasion by Bacteria Serratia grimesii. Biochemistry (Mosc). 2019 Jun;84(6):663-671. doi: 10.1134/S0006297919060099. PMID: 31238866.
3: Timmermans-Sprang EPM, Mestemaker HM, Steenlage RR, Mol JA. Dasatinib inhibition of cSRC prevents the migration and metastasis of canine mammary cancer cells with enhanced Wnt and HER signalling. Vet Comp Oncol. 2019 Sep;17(3):413-426. doi: 10.1111/vco.12490. Epub 2019 Jun 13. PMID: 31069942.
4: Tomilov A, Allen S, Hui CK, Bettaieb A, Cortopassi G. Idebenone is a cytoprotective insulin sensitizer whose mechanism is Shc inhibition. Pharmacol Res. 2018 Nov;137:89-103. doi: 10.1016/j.phrs.2018.09.024. Epub 2018 Oct 2. PMID: 30290222.
5: He H, Huh J, Wang H, Kang Y, Lou J, Xu Z. Mitochondrial events responsible for morphine's cardioprotection against ischemia/reperfusion injury. Toxicol Appl Pharmacol. 2016 Jan 1;290:66-73. doi: 10.1016/j.taap.2015.11.019. Epub 2015 Nov 26. PMID: 26631580.
6: Timmermans-Sprang EP, Gracanin A, Mol JA. High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 overexpression. BMC Cancer. 2015 Jul 25;15:545. doi: 10.1186/s12885-015-1544-y. PMID: 26205886; PMCID: PMC4513708.
7: Chen X, Ren Z, Liang W, Zha D, Liu Y, Chen C, Singhal PC, Ding G. c-Abl mediates angiotensin II-induced apoptosis in podocytes. J Mol Histol. 2013 Oct;44(5):597-608. doi: 10.1007/s10735-013-9505-8. Epub 2013 Mar 21. PMID: 23515840; PMCID: PMC3758790.
8: Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315. doi: 10.1042/BJ20070797. PMID: 17850214; PMCID: PMC2267365.
